Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 799-809

  Guo, Feng ^a   Letrent, Stephen P ^a   Sharma, Amarnath ^a  

^a PFIZER INC   (United States)

Author keywords

HER2 tyrosine kinase inhibitor; Population pharmacokinetics

Indexed keywords

CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; FEMALE; HUMAN; LIVER METASTASIS; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BODY WEIGHT; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTICENTER STUDIES; NEOPLASMS; NONLINEAR DYNAMICS; QUINAZOLINES; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION;

EID: 34548598185     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0427-6     Document Type: Article

References (28)

1. Slamon DJ, Clark GM (1988) Amplification of c-erbB-2 and aggressive human breast tumors. Science 240:1795-1798
2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
3. Baselga J, Tripathy D, Mendelsohn J et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83
4. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
6. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
7. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
8. Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221
9. Jani JP, Barbacci G, Bhattacharya S, Boos C, Campbell M, Clark T, Coleman K, Currier N et al (2004) CP-724714, a novel erbB2 receptor tyrosine kinase inhibitor for cancer therapy. Proc Am Assoc Cancer Res 45:1071
10. Guo F, Letrent S, Noe D, Qin A, Rohrbacher K, Munster PN, Tolcher AW, Britten CD, Gelmon K, Sharma A (2006) Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Clin Pharmacol Ther 79:P10
11. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW (2006) First-in-human study of the safety and tolerability and pharmacokinetics of CP-724,714 in patients with advanced malignant solid tumors that express HER2. Clin Cancer Res (in press)
12. Bruno R, Hille D, Riva A, Vivier N, Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas FR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196
13. Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20:4065-4073
14. Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A (2001) Role of modeling and simulation in Phase I drug development. Eur J Pharm Sci 13:115-122
15. Williams PJ, Ette EI (2000) The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's "Guidance for Industry: population pharmacokinetics". Clin Pharmacokinet 39:385-395
16. Beal SL, Sheiner LB (1998) NONMEM user's guide: NONMEM project group. University of California, San Francisco
17. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735-750
18. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495
19. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
20. Holford NH (2005) The visual predictive check-superiority to standard diagnostic plots, the 2005 Population Approach Group In Europe (PAGE) annual meeting, Abstr 738, Pamplona, Spain
21. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19-29
22. Gibiansky E, Gibiansky L, Enriquez J (2005) Population pharmacokinetic model of sedative doses of GPI 15715 and propofol liberated from GPI 15715, the 2005 ASCPT annual meeting, Abstr PI-154, Orlando
23. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H (2002) Population pharmacokinetic model for irinontecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 72:638-647
24. Launay-Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, LeBail N, Iliadis (1995) A population pharmacokinetics of docetaxel during phase 1 studies using nonlinear mixed-effect modeling and nonparameteric maximum-likelihood estimation. Cancer Chemother Pharmacol 37:47-54
25. Chen XY, Bies RR, Ramanathan RK, Zuhowski EG, Ttrmp DL, Egorin MJ (2005) Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advance malignancies. Cancer Chemother Pharmacol 55:237-243
26. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 32:185-209
27. Ette CI, Williams PJ (2004) Population pharmacokinetics II: estimation methods. Ann Pharmacother 38:1907-1915
28. Ribbing J, Jonsson EN (2004) Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 1:109-134